1. Home
  2. Labeler Index
  3. Aphena Pharma Solutions - Tennessee, Llc
  4. 71610-177
  5. Product Images: Jardiance

Product Images Jardiance

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Jardiance NDC 71610-177 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Bottle Label 25 mg - 71610 0177 09

Bottle Label 25 mg - 71610 0177 09

Aphena Pharma Solutions - TN - Aphena

Aphena Pharma Solutions - TN - Aphena

Empagliflozin structure - empagliflozin structure

Empagliflozin structure - empagliflozin structure

figure-1 - figure 1

figure-1 - figure 1

figure-2 - figure 2

figure-2 - figure 2

Figure 3 - figure 3

Figure 3 - figure 3

The text provides a table showing the mean change from baseline HbA1c (%) over a 24-week period. The data compares a placebo group (N=185) to two groups treated with Empagliflozin (10mg and 25mg respectively) with N=206 and N=202. The data is adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*

Figure 4 - figure 4

Figure 4 - figure 4

The text describes the mean change from baseline HbA1c (%) values for two different treatments: Glimepiride + Metformin and Empaglifiozin 25 mg + Metformin. There are values shown for weeks 4, 12, 28, and 52. The values are adjusted for baseline HbA1c, geographical region, and eGFR at baseline.*

Figure 5 - jardiance figure 5

Figure 5 - jardiance figure 5

Figure 5 shows the cumulative incidence of first MACE (major adverse cardiovascular events) in patients treated with placebo and empagliflozin. The percentage of patients with events is shown on the left, while the subjects at risk are displayed on the bottom row. The chart includes two lines, one for placebo and one for empagliflozin. The x-axis represents time in months. Unfortunately, no further information is available in the given text.*

Figure 6 - jardiance figure 6

Figure 6 - jardiance figure 6

This is a graph showing the estimated cumulative incidence of cardiovascular death in patients taking a placebo versus those taking Empagliflozin over a period of 48 months. It also shows the number of patients with an event as a percentage.*

qr-code - qr code

qr-code - qr code

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.